IL23A and Hematochezia: Deucravacitinib is a TYK2 inhibitor that modulates inflammatory signals by IL-12 and IL-23, which was recently tested in a phase 2 study (LATTICE-UC) in moderately to severely active UC (modified Mayo Score of 5 to 9: endoscopic subscore ≥ 2, rectal bleeding subscore ≥ 1, stool frequency subscore ≥ 2) [51].